The viral illness kills more people in the city than HIV, but antiviral medications may be helping cut its transmission.

Viral hepatitis is a major danger to public health. According to WHO’s 2024 Global Hepatitis Report, viral hepatitis deaths ...

In Europe, the introduction of HBV vaccination has markedly reduced the incidence of acute HBV ... [1] Since 1992, the inclusion of hepatitis B vaccination has been recommended by the WHO in ...

Chronic hepatitis B (CHB) remains a significant global health challenge, and effective antiviral therapies are essential for long-term management. This study aimed to evaluate the real-world ...

Today, nearly 300 million people worldwide live with chronic hepatitis B (CHB), the complications of which cause approximately one death every 30 seconds 1. In addition to living with a ...

A Seattle biotech company is working on a tweak to gene expression that could shut down hepatitis B (HBV), one of the viruses ...

 While hepatitis A and E cause an acute form of the disease, hepatitis B and C lead to chronic liver disease including cirrhosis and even liver cancer. On World Liver Day, April 19, here's ...

The American Gastroenterology Association (AGA) updated its clinical practice guidelines for managing hepatitis B ...

Collaboration with South Korean university advocates early antiviral treatment for hepatitis B | Feb. 5, 2025 13:09 ...

Existing treatment criteria for chronic hepatitis B virus (HBV) infection are mainly based on data from observational studies, such as the REVEAL study from Taiwan, which was initiated in the early ...

Discover a clinical trial that was conducted to evaluate the efficacy and safety of autologous HBV vaccine-pulsed dendritic cells and their induced T cells.

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).